ClinicalTrials.gg
CompletedNCT01424930Updated Jul 25, 2014Results posted

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 interventional study of Abiraterone and Prednisone in Prostate Neoplasms and Prostate Cancer, sponsored by Janssen-Ortho Inc., Canada. Completed at 2 sites in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-25.

Sponsored by Janssen-Ortho Inc., Canada (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing abiraterone in Prostatic Neoplasms — 17 open to participants now, 37 under way, 5 of them phase 3. abiraterone · Prostatic Neoplasms.

Enrollment
96th of 126
25 · median 51
Started
2011
with 5 others
Phase 2
79 of 126
13 open now
Registered
19th of 126
by date

Among the 126 studies testing abiraterone in Prostatic Neoplasms, this one is the 96th largest by enrollment, is one of 6 that started in 2011, is one of 79 in phase 2, and was the 19th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 126 studies testing abiraterone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About abiraterone

abiraterone: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing abiraterone in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to establish the safety profile of oral (by mouth) abiraterone acetate and oral prednisone following short-term administration after standardized low-fat or high-fat meals to patients with metastatic (spreading) castration-resistant prostate cancer (mCRPC).

Read the detailed description

This is a multicenter, open-label study of 24 (up to a total of 28) men to assess the short-term safety of oral abiraterone acetate 1 g and oral prednisone 5 mg twice daily administered in the modified fasted state and after meals of various fat contents. All patients will take daily abiraterone acetate for the first 7 days in the modified fasted state (no food for 2 hours before and 1 hour after the dose). In Cohort 1, up to 6 evaluable patients will take abiraterone acetate daily for 7 days after a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14; or, in Cohort 2, up to 6 evaluable patients will take abiraterone acetate daily for 7 days after a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. All patients will then continue to take abiraterone acetate daily in the modified fasted state starting on Cycle 1 Day 15 until disease progression. Toxicity related to dosing after the low-fat or high-fat meals is defined as Grade 3 or higher AEs of special interest; or Grade 3 or higher serious adverse events (SAEs) that occur during the food safety evaluation period. Cohort 2 may be expanded to a total of 18 evaluable patients if deemed to be safe. Decisions regarding the escalation of cohort or expansion of cohorts will be made by a study evaluation team. Pharmacokinetic evaluation for each cohort will be performed on Cycle 1 Days 7 and 14 at predose and multiple timepoints postdose over 24 hours; Cycle 1 Days 8 and 11 at 2 hours following abiraterone acetate dose administration. Abiraterone acetate, 1 g (four 250-mg tablets) orally (taken by mouth) once daily. Patients may take abiraterone acetate until progression of clinical disease. Prednisone, 5 mg, orally, twice a day.

03

Conditions studied

  • Prostate Neoplasms
  • Prostate Cancer

Browse trials for

Keywords

  • Metastatic castration-resistant prostate cancer
  • CRPC
  • Abiraterone Acetate
  • Prednisone
  • Food Safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adenocarcinoma of the prostate
  • disease documented by bone, computed tomography (CT) or magnetic resonance imaging (MRI) scan
  • Surgical or medical castration with testosterone less than 50 ng/dL (\< 2.0 nM)
  • Prostate-specific antigen (PSA) or radiographic progression documented by assessments specified in study protocol
  • >100,000/µl
  • >=9.0 g/dL
  • Liver function tests (LFTs): Serum \< 1.5 x ; or ALT \< 2.5 x ULN; (ECOG) status score of \<=2

Exclusion criteria

Exclusion Criteria:

  • Small cell carcinoma of the prostate
  • Known , chronic liver disease with elevated LFTs
  • Prior cytotoxic chemotherapy for prostate cancer
  • Treatment of prostate cancer within 30 days of Day 1 Cycle 1 with surgery, radiation, chemotherapy or immunotherapy
  • Use of drug within 30 days of Day 1 Cycle 1 or current enrollment in an investigational drug or device study
  • Recent history of ischemic heart disease, (ECG) abnormalities or atrial fibrillation
  • Active infection or other medical condition that would make prednisone () use
  • Chronic medical condition requiring a higher dose of corticosteroid than prednisone 5 mg twice daily
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Abiraterone+prednisone (low-fat meal)

    Participants will receive abiraterone acetate at a starting dose of 1,000 milligram (mg) once daily for 7 days post 30-minutes of a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.

    Drug: Abiraterone · Drug: Prednisone

  • Experimental
    Abiraterone+prednisone (high-fat meal)

    Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.

    Drug: Abiraterone · Drug: Prednisone

Interventions

  • Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.

  • Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication

    AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events.

    Time frame: Postdose on Cycle 1 Day 8 to predose on Cycle 2 Day 1

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Abiraterone

    The table below shows mean Cmax of Abiraterone. The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.

    Time frame: Day 7 and Day 14

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone

    The table below shows median Tmax of Abiraterone. The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.

    Time frame: Day 7 and Day 14

  3. Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)

    The table below shows mean AUC24h. The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption.

    Time frame: Day 7 and Day 14

07

Results

Posted Apr 30, 2014

Participant flow

The study was conducted from 29 September 2011 to 29 May 2013. Participants were recruited at 2 study centers in Canada.

Participant flow — Overall Study
MilestoneAbiraterone+Prednisone (Low-fat Meal)Abiraterone+Prednisone (High-fat Meal)
Started718
Completed food safety evaluation618
Completed34
Not completed414
Withdrew: Adverse event01
Withdrew: Death10
Withdrew: Progressive disease36
Withdrew: Screen failure01
Withdrew: Reason not specified06

Outcome measures

PrimaryNumber of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication

AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events.

Time frame:
Postdose on Cycle 1 Day 8 to predose on Cycle 2 Day 1
Reported as:
Number · Participants
Number of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication
ParticipantsAbiraterone+Prednisone (Low-fat Meal)Abiraterone+Prednisone (High-fat Meal)
Number of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication00
SecondaryMaximum Observed Plasma Concentration (Cmax) of Abiraterone

The table below shows mean Cmax of Abiraterone. The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.

Time frame:
Day 7 and Day 14
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Abiraterone
ng/mLAbiraterone+Prednisone (Low-fat Meal)Abiraterone+Prednisone (High-fat Meal)
Day 7218 ± 168196 ± 234
Day 14265 ± 229342 ± 289
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone

The table below shows median Tmax of Abiraterone. The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.

Time frame:
Day 7 and Day 14
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone
hoursAbiraterone+Prednisone (Low-fat Meal)Abiraterone+Prednisone (High-fat Meal)
Day 72 ± 1.0 - 8.12 ± 0.5 - 6.0
Day 142.5 ± 1.0 - 3.04.0 ± 3.0 - 10.0
SecondaryArea Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)

The table below shows mean AUC24h. The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption.

Time frame:
Day 7 and Day 14
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)
ng*h/mLAbiraterone+Prednisone (Low-fat Meal)Abiraterone+Prednisone (High-fat Meal)
Day 71271 ± 1279973 ± 667
Day 141264 ± 9631992 ± 720

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abiraterone+Prednisone (Low-fat Meal)—4/7 (57.1%)7/7 (100%)
Abiraterone+Prednisone (High-fat Meal)—4/18 (22.2%)18/18 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventAbiraterone+Prednisone (Low-fat Meal)Abiraterone+Prednisone (High-fat Meal)
Myocardial InfarctionCardiac disorders1/70/18
VomitingGastrointestinal disorders1/70/18
Lobar PneumoniaInfections and infestations1/70/18
PneumoniaInfections and infestations1/71/18
ArthralgiaMusculoskeletal and connective tissue disorders1/70/18
Bone PainMusculoskeletal and connective tissue disorders1/70/18
Muscular WeaknessMusculoskeletal and connective tissue disorders1/70/18
DeliriumPsychiatric disorders1/71/18
Small Intestinal ObstructionGastrointestinal disorders0/71/18
FatigueGeneral disorders0/71/18
Most frequent other events
Showing 10 of 131
Most frequent other events
EventAbiraterone+Prednisone (Low-fat Meal)Abiraterone+Prednisone (High-fat Meal)
HypokalaemiaMetabolism and nutrition disorders5/77/18
FatigueGeneral disorders3/711/18
ConstipationGastrointestinal disorders4/77/18
DiarrhoeaGastrointestinal disorders4/76/18
NauseaGastrointestinal disorders4/77/18
Oedema PeripheralGeneral disorders4/76/18
Decreased AppetiteMetabolism and nutrition disorders4/78/18
Back PainMusculoskeletal and connective tissue disorders4/77/18
Bone PainMusculoskeletal and connective tissue disorders4/72/18
ArthralgiaMusculoskeletal and connective tissue disorders3/78/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Abiraterone+Prednisone (Low-fat Meal)Abiraterone+Prednisone (High-fat Meal)Total
Mean75.1 ± 11.0169.1 ± 7.2670.8 ± 8.67
Sex: Female, Male
Sex: Female, Male(Participants)Abiraterone+Prednisone (Low-fat Meal)Abiraterone+Prednisone (High-fat Meal)Total
Female000
Male71825
08

Study locations

2 sites
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Apr 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2011
First posted
Aug 29, 2011
Start
Oct 2011
Primary completionActual
Apr 2013
CompletionActual
May 2013
Results first posted
Apr 30, 2014
Last update
Jul 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01424930
Responsible party
Sponsor
First posted
Aug 29, 2011
Start date
Oct 2011
Primary completion
Apr 2013
Completion
May 2013
Results posted
Apr 30, 2014
Last update
Jul 25, 2014

Study contacts

Janssen-Ortho, Canada Clinical Trial
study director · Janssen-Ortho Inc., Canada

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone · Prednisone

Start the discussion